A T cell-dependent immune response to group C meningococcal capsular polysaccharide (CPS) can be elicited when CPS is conjugated to the class 3 neisserial porin (CPS-porin). Treatment of CPS-porin-immunized mice with B7-2 blocking monoclonal antibody (MAb) caused a dramatic reduction in the CPS-specific IgG response, treatment with anti-B7-1 MAb had no effect, and concurrent blockade of B7-1 and B7-2 resulted in a synergistic abrogation of the CPS-specific IgG response while the CPS IgM response was unaffected. Anti-CD40L MAb treatment caused a significant reduction of both CPS-specific IgG and IgM levels. In contrast, blockade of CTLA4 interactions resulted in increases in both CPS IgG and IgM responses in CPS-porin-immunized mice. These data support the hypothesis that the ability of neisserial porins to improve the immune response to poorly immunogenic antigens (e.g., polysaccharides) is related to porin-induced increases in B7-2 expression on antigen-presenting cells and enhanced B/T cell interactions.
vitro [5] , thereby increasing the capacity of the B cells to costimulate T cells. B7-mediated costimulation of T cells by antigen-presenting cells (APCs) lowers the threshold number of T cell receptors that must be triggered for a T cell response to be generated to a given dose of antigen, thus making T cells more sensitive to antigenic stimulation and, consequently, enhancing the immune response [7] .
Our hypothesis has been that the immunopotentiating ability of porins is at least in part mediated through porin induction of B7-2 costimulatory ligand surface expression. During a T cell-dependent immune response, APCs recruit T cell help through a set of specific signals [8] . The first signal is via the presentation of processed antigen in the context of class II major histocompatibility complex on APCs to the T cell receptor on T cells. This signal confers antigen specificity. The second signal is mediated by costimulatory molecules present on APCs, B7-1 and B7-2. Both of these ligands can interact with their counter-receptors, CD28 and CTLA4, on T cells. B7-1 and B7-2 are differentially expressed on APCs. B7-2 is constitutively expressed on resting monocytes [9, 10] and dendritic cells [11, 12] . Although naive B cells do not express B7-1 or B7-2, expression can be induced upon B cell activation [9, 13] . Following induction, B7-2 is expressed earlier than B7-1 [14] . The early expression of B7-2 has led to the hypothesis that B7-2 may be more important in inducing an immune response, whereas B7-1 may function to regulate the response [15, 16] .
Data indicate that the costimulatory ligands B7-1 and B7-2 can deliver both activating and inhibitory signals to T cells [17, 18] . Engagement of the CD28 receptor on T cells by B7 molecules on APCs provides an activating signal, whereas CTLA4 engagement transduces a negative signal [19, 20] . CD28 is ex-pressed constitutively on resting T cells, whereas CTLA4 expression is only apparent 24-48 h after T cell activation [20] .
Immunization studies using B7-1 and B7-2 single or double knockout (KO) mice strongly suggest that the up-regulation of B7-1 and/or B7-2 by adjuvants enhances T/B cell collaborations critical for a humoral immune response [21] , since in B7-1/B7-2 double KO mice there is an absence of immunoglobulin class switching and germinal center formation after immunization with a hapten-protein conjugate [22] . However, in such studies by use of mice in which the B7-1 and/or B7-2 genes are absent, one cannot rule out the influence of the lack of these molecules on the maturation of various immune cells (e.g., T cells), possibly altering their effector functions and confounding experimental outcomes.
The impetus of this study was to determine the involvement of costimulatory interactions between APCs and T cells, specifically the influence of B7-2 expression on the adjuvant effect of the neisserial porins, by blocking costimulatory ligand interactions in wild type mice with specific monoclonal antibodies (MAbs) (as opposed to using specific KO mice for the reasons stated above). Mice were immunized with meningococcal group C polysaccharide (CPS) conjugated to porin (CPS-porin), and B7/CD28, B7/CTLA4, or CD40/CD40L interactions were concurrently or sequentially blocked by use of MAbs specific for B7-1, B7-2, CD40L, or CTLA4. The effect of ligand blockade on the immunopotentiating effect of the porin was determined by measuring anti-CPS antibody response induced in mice by the CPS-porin vaccine.
Materials and Methods
Animals. C3H/Hej mice were obtained from Jackson Laboratory (Bar Harbor, ME) and were used at 6-8 weeks of age. These lipopolysaccharide (LPS) nonresponsive mice [23] were used in all experiments to prevent the confounding effects of possible contamination of LPS in the porin preparations.
Antibodies. The rat anti-murine B7-1 MAb (1G10) [24] and anti-murine B7-2 MAb (2D10) [25] were originally made at Roche Research Center (Nutley, NJ; gift of G. D. Powers) [26] . The hamster anti-murine CD40L MAb (MR1) [27] was supplied by Bioexpress (West Lebanon, NH). The anti-CTLA4 MAb [28] (gift of J. Bluestone, University of Chicago) was purified by TSD Bioservices (Germantown, NY) and is considered a blocking MAb and does not transduce a signal through CTLA4 [24] . Rat IgG (Sigma, St. Louis) was used as an antibody control for B7-1, B7-2, and CTLA4 MAbs; hamster IgG (Cappel, Durham, NC) was used as a control MAb for the anti-CD40L MAb. Alkaline phosphatase (AP)-conjugated goat anti-mouse IgG and IgM antibody (Sigma) and AP-conjugated goat anti-mouse IgG1, IgG2a, IgG2b, or IgG3 (Southern Biotechnology Associates, Birmingham, AL) were used to detect levels of anti-CPS antibodies by ELISA. Goat anti-mouse IgG F(ab')2-specific antibody (Jackson ImmunoResearch Laboratories, West Grove, PA) was used to capture total IgG or IgG isotypes on ELISA, and goat anti-mouse IgM F(ab')2-specific antibody (American Qualex, San Clemente, CA) was used to capture IgM on ELISA plates. Purified IgM (PharMingen, San Diego), IgG (Sigma), and IgG1, IgG2a, IgG2b, and IgG3 (Southern Biotechnology) were used to generate standard immunoglobulin curves by ELISA.
CPS-porin conjugate vaccine. Purified recombinant meningococcal class 3 porin [29] was conjugated to purified CPS in an 1 : 1 ratio by reductive amination [30] (North American Vaccine [NAV], Beltsville, MD).
Immunizations. C3H/HeJ mice ( ) were immunized with n ϭ 4 10 mg of purified CPS (NAV) or with 10 mg of CPS-porin. Injections were given subcutaneously (sc) at 0 and 3 weeks.
Treatment protocol. After sc immunization, groups of mice were injected intraperitoneally (ip) with 200 mg of either anti-B7-1 MAb, anti-B7-2 MAb, a combination of anti-B7-1 and anti-B7-2 (containing 200 mg of each MAb), or rat IgG control antibody. Mice received 3 doses per week of antibody as follows: (1) after immunization 1 (0-3 weeks) and discontinued 3 days before immunization 2, (2) after immunization 2 (3-5 weeks), or (3) after both immunizations (0-5 weeks; see figure 1 ). Other groups of mice were given an ip injection of 500 mg of anti-CD40L MAb or hamster IgG control as follows: (1) at immunization 1, (2) at immunization 2, or (3) at both immunizations (see figure 1) . Finally, separate groups of mice were injected ip with 2 doses per week of 200 mg of anti-CTLA4 MAb or rat IgG control antibody throughout the 5-week treatment protocol. The vaccination and antibody treatment protocols are outlined in figure 1 . In all groups of mice, sera were obtained before the first and second immunizations (week 3) and 2 weeks after immunization 2 (week 5). Anti-CPS antibody levels were evaluated in pooled sera from each group by ELISA (see below). Immunization and MAb treatment for each group were performed in duplicate. Results are expressed as the average of 2 separate experiments.
Antibody quantification.
For quantification of CPS-specific murine IgG and IgM antibodies, a variation of a previously described protocol [31] was used. Dynex Immulon 2 ELISA plates (Dynex, Chantilly, VA) were coated with 0.25 mg/mL CPS conjugated to human serum albumin (from NAV). IgG and IgM in test sera were detected by use of AP-conjugated goat anti-mouse IgG and anti-mouse IgM, respectively. Amounts of CPS-specific IgG antibody were quantified by comparison of the A405 of the test sample with a standard curve generated using known concentrations of IgG on plates coated with goat anti-mouse IgG F(ab')2-specific antibody. Similarly, CPS-specific IgM antibody was quantified by comparing the A405 of the test sample with a standard curve generated using known concentrations of IgM on plates coated with goat anti-mouse IgM F(ab')2-specific antibody. ELISAs from which the IgG and IgM standard curves were derived were developed concurrently with ELISAs of test sera by use of the same conjugated antibodies specific for IgG or IgM. Results are presented as micrograms per milliliter of CPS-specific antibody.
Determination of IgG subclasses. CPS-specific antibodies of the different IgG subclasses present in murine sera were determined as in the total IgG assay but with the following modifications. APconjugated goat anti-mouse specific for IgG1, IgG2a, IgG2b, or IgG3 were used to detect the antibody subclasses. Standard curves were generated for each IgG subclass on parallel ELISA plates coated with goat anti-mouse IgG F(ab')2-specific antibody using known concentrations of IgG1, IgG2a, IgG2b, and IgG3 standard ) n ϭ 4 were immunized subcutaneously (sc) with group C meningococcal capsular polysaccharide (CPS)-porin conjugate vaccine. Each mouse was given 10 mg of CPS conjugated to 10 mg of porin at weeks 0 and 3. Groups of mice were given 200-mg dose intraperitoneally (ip) of either B7-1 and/or B7-2 monoclonal antibody (MAb) or anti-CTLA4 MAb at times indicated. Control groups were given 200-mg ip doses of rat IgG antibody at same times (not shown). Separate groups of mice was given 500-mg ip doses of anti-CD40L MAb at indicated times. Control groups were given 500-mg ip dose of hamster IgG at same times (not shown). Sera were obtained from mice prior to each immunization (0 and 3 weeks) and 2 weeks after immunization 2 (5 weeks).
antibody. Levels of antibody in mouse sera were quantified by use of the appropriate standard curves as described above. Values are expressed as micrograms per milliliter of CPS-specific antibody.
Statistical methods. Average means and SDs were calculated by use of Excel computer software (Microsoft, Redmond, WA).
Results
To demonstrate the adjuvant activity of neisserial porin, C3H/Hej mice ( ) were immunized with either CPS or CPS n ϭ 4 conjugated to meningococcal class 3 (CPS-porin) at 0 and 3 weeks, and the IgG and IgM response was measured 2 weeks after the second immunization. There was no detectable CPSspecific IgG or IgM in mice immunized with CPS alone. In contrast, high amounts (1100 mg/mL) of CPS-specific IgG were found in pooled sera of mice immunized with CPS-porin experiments, including control mice in the blocking experiments listed below (see figure 2) .
To determine whether B7-2 and/or B7-1 interactions are involved in the immunopotentiating effect of porin onjugated to CPS, mice were immunized with CPS-porin interactions between B7-1 and B7-2 molecules and their counter-receptors (CD28 and CTLA4) were blocked with specific MAb at various times after immunization, as illustrated in figure 1 . The inhibitory effects of ligand blockade on the CPS-specific IgG levels in immunized mice were compared with those in mice given control antibody following immunization ( figure 2). Figures 2,  3 , and 4 show antibody levels in sera of mice sampled 2 weeks after the second immunization at week 5. CPS-specific antibody levels in sera sampled just before the second immunization at week 3 were very low (!10 mg/mL; data not shown). Blocking of B7-2 interactions for the entire protocol (after immunizations 1 and 2) inhibited production of CPS-specific IgG in immunized mice by 180%, decreasing the levels from mg/mL 148.1 ‫ע‬ 33.8 in mice given control antibody to mg/mL in B7-2 23.9 ‫ע‬ 21.9 MAb-treated mice (figure 2). In contrast, treatment of mice with B7-1 MAb after immunizations 1 and 2 did not significantly affect CPS-specific IgG levels ( mg/mL). 123.9 ‫ע‬ 46.6 When B7-2 was blocked only after the second immunization, the IgG response to CPS was inhibited by 50% (figure 2). However, when B7-2 interactions were blocked only after the first immunization but not after the second immunization, levels of CPS-specific IgG were unaffected when compared with those in immunized mice given control antibody. Treatment with B7-1 or B7-2 MAb individually did not significantly affect the relative ratio of the IgG isotypes (IgG1, IgG2a, IgG2b, or IgG3) produced toward CPS in CPS-porin -immunized mice (data not shown).
When both B7-1 and B7-2 interactions were blocked simultaneously throughout the protocol (after immunizations 1 and 2) or only during the primary response (after the first immunization but not the second), the levels of CPS-specific IgG were reduced by !95% to !1 mg/mL (figure 2). However, blockade of both B7-1 and B7-2 interactions simultaneously only after the second immunization inhibited the IgG response by just 60%, compared with mice receiving control antibody (figure 2). Simultaneous blockade of B7-1 and B7-2 interactions in CPS-porin-immunized mice had no inhibitory effect on the specific IgM response to CPS (figure 3). Similar levels of CPSspecific IgM were found in pooled sera from anti-B7-1/anti-B7-2 MAb-treated mice, compared with levels of ∼3 mg/mL in mice given control antibody (figure 3).
CD40L on T cells promotes isotype switching and affinity maturation when bound to CD40 on APCs and is an absolute requirement for a T cell-dependent response [32] . Treatment with anti-CD40L MAb resulted in almost complete inhibition (195%) of the anti-CPS-specific IgG response in mice given CPS-porinine when given after the first, second, or both immunizations (figure 2). Anti-CD40L MAb treatment of immunized mice also greatly decreased the CPS-specific IgM response levels to !1 mg/mL when given after the first, second, or both immunizations ( figure 3 ). This was in contrast to CPSporin-immunized mice treated with anti-B7-1 and -B7-2 MAb concurrently: they had a reduction in CPS-specific IgG response but no change in CPS-specific IgM levels ( figure 3) .
To investigate the role of CTLA4 ligand on T cells in the induction of a humoral response to CPS in mice immunized with CPS-porinA4 ligand was blocked with specific MAb given ip, as illustrated in figure 1. When measured at week 5 after initial immunization with CPS-porina of mice given CTLA4-blocking MAb had mg/mL of CPS-specific IgG 582.9 ‫ע‬ 182.0 antibody, nearly a 3-fold increase compared with amounts ( mg/mL) in sera of mice given control antibody 181.1 ‫ע‬ 1.2 ( figure 4A ). Of interest, treatment of immunized mice with CTLA4-blocking MAb also enhanced the IgM immune response to CPS, increasing it by 11.5-fold from mg/ 2.2 ‫ע‬ 0.4 mL of anti-CPS IgM antibody in sera of mice given control antibody, compared with mg/mL in mice given anti-3.9 ‫ע‬ 0.1 CTLA4 MAb (figure 4B).
Discussion
Although adjuvants have been used empirically for many years, the mechanism of action of many of these adjuvants is not well defined [33] . Elucidation of such mechanisms responsible for the immunopotentiating effects of adjuvants, such as neisserial porinessential for the development of improved vaccines. In this study, we demonstrated that neisserial porin conjugated to CPS could induce a robust T cell-dependent response toward CPS, without the requirement of additional adjuvant. Moreover, there was clear demonstration that the observed immunopotentiating ability of the porinnjugated to CPS) was dependent on B7-2 expression by APC, since after immunization of mice with CPS-porin vaccine, blockade of B7-2 interactions dramatically reduced the IgG response to CPS. This was consistent with our previous in vitro data demonstrating that neisserial porins cause up-regulation of the B7-2 costimulatory li- gand on murine B cells and, as a consequence, increase the ability of B cells to costimulate T cells [5] .
The requirement for B7-2 interactions in T cell-dependent responses toward normally T cell-independent antigens induced by conjugate vaccines has been demonstrated in other in vivo systems [22, 34] . However, with other conjugate vaccines, the extent of inhibition of the IgG response after B7-2 blockade was not nearly as profound as that observed in mice immunized with CPS-porin conjugate vaccine. In studies of mice immunized ip with alum-precipitated (4-hydroxy-3-nitrophenyl) acetyl-chicken g-globulin (NP-HG), Han et al. [34] showed a 50% reduction in primary antibody specific for NP as a consequence of anti-B7-2 blockade. In B7-2-deficient mice immunized intravenously or ip with hapten-protein conjugate, 2,4,6-trinitrophenol (TNP) keyhole limpet hemocyanin (KLH) or TNP ovalbumin adsorbed to alum, the TNP-specific response was attenuated. However, when mice were immunized sc, as in the present study, even in the presence of adjuvant (alum), the humoral response was unaffected by anti-B7-2 MAb treatment, compared with that in wild type mice. This indicates that although important, B7-2 expression is not an absolute requirement for induction of immune responses for all conjugate vaccines, but, as demonstrated in the present study, specifically functions in the immunopotentiating effect of the porin in the porin-CPS conjugate vaccine.
The data described above do not rule out the possibility that, at least in part, the immunopotentiating ability of the porin in the porin-polysaccharide conjugate vaccine is due to a vaccine carrier effect and not due to any inherent adjuvant ability of the porin. Nevertheless, our previous work showed that the humoral immune response toward group C meningococcal polysaccharide can be greatly enhanced even when the immunogens are noncovalent complexes of neisserial porin and group C meningococcal polysaccharide [4] . This indicates that conjugation of the porin to the polysaccharide is not an absolute requirement for the enhancement of the humoral immune response toward the capsular polysaccharide induced by the porin. However, the response to the polysaccharide when the noncovalent porin-polysaccharide complex is used is less than the response shown in the present study. This suggests that when the porin is conjugated to the polysaccharide, the increase in the humoral immune response to the polysaccharide moiety could be due to the potential inherent adjuvant effect of the porin (mediated by B7-2/CD28 interactions), along with a specific carrier effect due to the conjugation The IgG response to CPS in CPS-porin-immunized mice was unaffected by blockade of B7-1. This was consistent with previous findings in B7-1 KO mice, which exhibited a normal humoral response when vaccinated with TNP protein conjugate vaccines, compared with that of wild type mice [22] . In mice immunized with the CPS-porin conjugate vaccine, blockade of B7-2 interactions after the first immunization, but not after the second, did not affect anti-CPS IgG levels, suggesting that B7-1 and B7-2 can compensate for each other in the development of memory B cells during the response to CPS when conjugated to porin. However, when B7-2 ligand was blocked after the second immunization but not after the first immunization, the IgG response to CPS was inhibited by 50% (figure 2), suggesting that in this system, B7-2 is critical in the recall response to CPS when conjugated to porin.
When both B7-1 and B7-2 were blocked concurrently after the primary vaccination (0-3 weeks), the CPS-specific IgG response was almost completely abolished. This finding suggests that at least one of these ligands must be expressed for production of a memory response. This was confirmed when CPSporin-vaccinated mice were treated with either B7-1 or B7-2 MAb, after the first immunization (0-3 weeks) but not after the second. In both instances, the CPS-specific IgG response was unaffected, compared with that of immunized mice given the control antibody. Synergistic inhibition of a Th2-type immune response following simultaneous blockade of both B7 ligands has been observed in other experimental systems both in vitro [35] and in vivo [22, 36] . Inhibition was found in studies using TNP-KLH-immunized B7-1/2 double KO mice. The mice exhibited a profound defect in isotype switching accompanied by an absence of germinal center formation regardless of vaccine immunization route or presence of adjuvant [22] . The requirement of at least one of the ligands, B7-1 or B7-2, is characteristic of many different types of immune responses and is not unique to the response to CPS when conjugated to porin. It is not known if this is a direct effect of the interaction of these ligands with CD28/CTLA4 or an indirect effect involving the CD40-CD40L interaction, since the interaction of B7-1 and B7-2 with CD28 on T cells can cause up-regulation of CD40L expression on T cells [37] . Conversely, ligation of CD40 on B cells (with CD40L or specific antibody) causes increased expression of B7-2 on murine splenic cells [38] .
In this study, anti-CD40L MAb treatment also abolished the humoral response to the polysaccharide moiety of the CPSporin vaccine, confirming that the anti-polysaccharide response was T cell dependent and consistent with previous findings that used CD40L and CD40 KO mice [39, 40] . In these mice, humoral responses to T cell-dependent antigens, including immunoglobulin class switching and germinal center formation, were impaired. Moreover, in our studies, CPS-specific IgM responses were decreased in mice treated with anti-CD40L MAb, indicating that CD40L is also involved in the IgM response to CPS in mice immunized with the CPS-porin conjugate vaccine. This finding contradicts current dogma, which suggests that most if not all IgM responses are T cell independent. In contrast to anti-CD40L MAb treatment, anti-B7-1 and anti-B7-2 MAb treatment did not affect the IgM response to CPS in mice immunized with the vaccine, suggesting differential pathways for the control of the CPS-specific IgM response induced by the porin-conjugate vaccine. When mice were treated with anti-CD40L only after the first immunization (0-3 weeks), they failed to respond to the boost of CPS-porin vaccine given at 3 weeks, indicating that CD40L is required to establish initiation of a response to CPS when conjugated to porin. A recent study that tracked specific B and T cells populations after immunization of mice with chicken ovalbumin coupled to hen egg lysozyme [41] found that blocking CD40-CD40L interactions with anti-CD40L MAb in vivo completely inhibited clonal expansion and antibody production of specific B cells but inhibited clonal expansion of specific T cells by 50%.
CTLA4, another B7 counter-receptor present on T cells, has homology to the CD28 ligand [42] . Ligation of CTLA4 is thought to impart a negative signal to the T cell [19, 20] . Consistent with this finding, we demonstrated that blockade of CTLA4 resulted in у3-fold increase in CPS-specific IgG and a 1.7-fold increase in CPS-specific IgM levels in mice immunized with CPS-porin vaccine. From this we postulated that CTLA4 is involved in controlling the response to CPS in mice immunized with the CPS-porin conjugate and specifically functions to down-regulate the T cell-dependent response to CPS. We believe this report is the first to demonstrate that CTLA4 interactions function to down-regulate the IgG and IgM response to a T cell-independent antigen when conjugated to porin. This has wide ranging implications for therapy against infectious diseases.
This report highlights the key role of B7-2 costimulatory ligand expression in the immunopotentiating ability of neisserial porin in vivo and presents an in-depth analysis of how costimulatory signals (positive and negative) function to regulate the humoral immune response with a T cell dependent to a polysaccharide conjugate vaccine containing neisserial porin. This study elucidated the role of various costimulatory signals between APCs and T cells in the immune response to a conjugate vaccine containing neisserial porin, a major new carrier and potential adjuvant currently being used in various vaccine preparations [3, [43] [44] [45] , and specifically identified B7-2 expression on APC as the central component in the immunopotentiating effect of neisserial porins.
